{
  "ticker": "KURA",
  "company_name": "Kura Oncology, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT02779777",
      "title": "Tipifarnib in Subjects With Myelodysplastic Syndromes",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Myelodysplastic Syndromes",
      "start_date": "2016-06-01",
      "completion_date": "2018-08-28",
      "enrollment": 0,
      "sponsor": "Kura Oncology, Inc."
    },
    {
      "nct_id": "NCT03051035",
      "title": "First-in-Human Study of KO-947 in Non-Hematological Malignancies",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Advanced Malignant Neoplasm",
      "start_date": "2017-04-06",
      "completion_date": "2020-06-02",
      "enrollment": 0,
      "sponsor": "Kura Oncology, Inc."
    },
    {
      "nct_id": "NCT05693090",
      "title": "Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer",
      "status": "WITHDRAWN",
      "phase": "PHASE1",
      "condition": "NSCLC",
      "start_date": "2023-02-01",
      "completion_date": "2027-07-27",
      "enrollment": 0,
      "sponsor": "Kura Oncology, Inc."
    },
    {
      "nct_id": "NCT05848687",
      "title": "TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Lymphoblastic Leukemia",
      "start_date": "2023-11-03",
      "completion_date": "2033-12",
      "enrollment": 0,
      "sponsor": "Tanja Andrea Gruber"
    },
    {
      "nct_id": "NCT06930352",
      "title": "Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy",
      "status": "NOT_YET_RECRUITING",
      "phase": "PHASE2",
      "condition": "Acute Myeloid Leukemia",
      "start_date": "2026-01-10",
      "completion_date": "2027-12-31",
      "enrollment": 0,
      "sponsor": "Uma Borate"
    },
    {
      "nct_id": "NCT07355335",
      "title": "Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML",
      "status": "NOT_YET_RECRUITING",
      "phase": "PHASE1",
      "condition": "KMT2A-rearranged, NPM1-mutant Refractory or Relapsed AML",
      "start_date": "2026-07-09",
      "completion_date": "2028-01-01",
      "enrollment": 0,
      "sponsor": "Massachusetts General Hospital"
    },
    {
      "nct_id": "NCT06655246",
      "title": "A Study of Ziftomenib, an Oral Menin Inhibitor, in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Tumor (GIST) of the Gastrointestinal Tract, Gastrointestinal Stromal Cancer, Gastrointestinal Stromal Neoplasm, Gastrointestinal Stromal Tumor, Malignant, Gastrointestinal Stromal Cell Tumors",
      "start_date": "2025-03-27",
      "completion_date": "2028-12",
      "enrollment": 0,
      "sponsor": "Kura Oncology, Inc."
    },
    {
      "nct_id": "NCT03719690",
      "title": "Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "HRAS Gene Mutation, HNSCC",
      "start_date": "2019-03-15",
      "completion_date": "2023-05-02",
      "enrollment": 0,
      "sponsor": "Kura Oncology, Inc."
    },
    {
      "nct_id": "NCT04997902",
      "title": "Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "HNSCC",
      "start_date": "2021-12-07",
      "completion_date": "2025-07-30",
      "enrollment": 0,
      "sponsor": "Kura Oncology, Inc."
    },
    {
      "nct_id": "NCT04809233",
      "title": "Expanded Access to Tipifarnib",
      "status": "AVAILABLE",
      "phase": "",
      "condition": "HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)",
      "start_date": "",
      "completion_date": "",
      "enrollment": 0,
      "sponsor": "Kura Oncology, Inc."
    }
  ],
  "summary": {
    "total_trials": 23,
    "by_phase": {
      "PHASE2": 6,
      "PHASE1": 11,
      "PHASE1, PHASE2": 3,
      "": 2,
      "PHASE3": 1
    },
    "by_status": {
      "TERMINATED": 3,
      "WITHDRAWN": 1,
      "RECRUITING": 10,
      "NOT_YET_RECRUITING": 2,
      "COMPLETED": 5,
      "AVAILABLE": 2
    },
    "active_trials": 10,
    "completed_trials": 5,
    "conditions": [
      "AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type",
      "Acute Lymphoblastic Leukemia, With Appropriate Mutations, Acute Myeloid Leukemia, With NPM1 Mutations",
      "Acute Myeloid Leukemia",
      "Acute Myeloid Leukemia (AML)",
      "Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma, Nucleophosmin 1-mutated Acute Myeloid Leukemia",
      "Advanced Malignant Neoplasm",
      "Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia, Acute Lymphoblastic Leukemia",
      "Advanced Solid Tumor",
      "Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Tumor (GIST) of the Gastrointestinal Tract, Gastrointestinal Stromal Cancer, Gastrointestinal Stromal Neoplasm, Gastrointestinal Stromal Tumor, Malignant, Gastrointestinal Stromal Cell Tumors",
      "HNSCC",
      "HRAS Gene Mutation, HNSCC",
      "HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)",
      "KMT2A-rearranged, NPM1-mutant Refractory or Relapsed AML",
      "Leukemia, Myelomonocytic, Chronic",
      "Lymphoblastic Leukemia",
      "Myelodysplastic Syndromes",
      "NSCLC",
      "Refractory Acute Leukemia, Pediatric Relapsed",
      "Relapsed or Refractory Peripheral T-Cell Lymphoma",
      "Relapsed/Refractory KMT2A-r Acute Leukemia, Relapsed/Refractory NUP98-r Acute Leukemia, Relapsed/Refractory NPM1-m Acute Leukemia",
      "Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Clear Cell Renal Cell Carcinoma (ccRCC), Renal Cell Carcinoma (Kidney Cancer), Non Clear Cell Renal Cell Carcinoma (nccRCC)",
      "Thyroid Cancer, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), HRAS Mutant Tumor, Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:19:31.255691",
    "search_query": "Kura Oncology, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Kura+Oncology,+Inc."
  }
}